2516 results about "Mortality rate" patented technology

Present invention is a system of blood glucose monitoring and intensive insulin therapy in a ICU for strict maintenance of normoglycemia which reduces intensive care and hospital mortality and morbidity of critically ill adult patients. The findings of present study also reveal factors determining insulin doses needed to maintain normoglycemia as well as the impact of insulin dose versus blood glucose level on the observed outcome benefits have been established. The invention provides a control system that adapts the flow of the insulin infusion based on insulin requirement calculated by blood glucose levels and clinical parameters such as history of diabetes, Body Mass Index, blood glucose level on admission, reason of ICU admission, time in the ICU, type and severity of illness, caloric intake, obesity, drugs affecting insulin sensitivity). This automated insulin monitoring systems significantly reduces the workload and human resource management problems for intensive insulin therapy in patients in the ICU.

A method for treating or preventing spontaneous preterm birth in pregnant women and improving neonatal morbidity and mortality. The method includes administering to a pregnant woman in need thereof an effective amount of progesterone sufficient to prolong gestation by minimizing the shortening or effacing of her cervix. Treatment and prophylaxis with progesterone in pregnant women having symptoms of short cervix has been clinically shown to increase neonatal health.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.

Biomarkers for sepsis and resulting mortality can be detected by assaying blood samples. Changes in the concentration of the biomarkers can be used to indicate sepsis, risk of sepsis, progression of sepsis, remission from sepsis, and risk of mortality. Changes can be evaluated relative to data sets, natural or synthetic or semisynthetic control samples, or patient samples collected at different time points. Some biomarkers' concentrations are elevated during disease and some are depressed. These are termed informative biomarkers. Some biomarkers are diagnostic in combination with others. Individual biomarkers may be weighted when used in combinations. Biomarkers can be assessed in individual, isolated or assays, in parallel assays, or in single-pot assays.

Devices and methods are provided for percutaneously treating atherosclerotic plaques within blood vessels. Atherosclerotic plaques cause significant morbidity and mortality by narrowing the arteries, which adversely affects blood flow, and by acting as a source for thrombi and emboli thus causing acute organ ischemia. Current treatments include open surgery with its inherent drawbacks, and stenting, which is less invasive but leaves the plaque material in the artery, which promotes restenosis. The present invention combines the advantages of both approaches. In general, the invention provides tools that enable percutaneously dissecting the plaque from the arterial wall and removing it from the body.

The present invention relates to a monitor respiration movements device to be used on humans and also on animals for controlling the respiration movements and to control the apnea periods on infants, wherein the device reduces the mortality rate caused by the sudden instant death syndrome (SIDS), wherein the device comprises an accelerometer and a micro controller, with the accelerometer including a motion detector and a plurality of output plugs, the micro controller includes a plurality of input sockets, and wherein the plurality of output plugs are connected to the plurality of input sockets and the micro controller includes signal outputs which are connected to an alarm.

The invention relates to a sucking pig compound feed and a preparation method thereof. The feed comprises the following raw materials in parts by weight: 30-90 parts of vegetable feed raw material, 25-80 parts of vegetable puffed feed, 5-25 parts of fermentation bean pulp, 2-10 parts of fish meal, 6-30 parts of dairy product, 1-4 parts of oil, 0.2-3 parts of amino acid, 0.01-0.05 part of liquid additive and 1-3 parts of solid additive. The preparation method of the feed provided by the invention can ensure the best use of the nutrient components of different materials, can overcome the instability of enzyme agents and microbial ecological agents caused by heating, and can effectively eliminate the indigestion caused by hyposecretion of digestive enzymes before and after the weaning of thesucking pig and improve the intestinal canal health as well as the pig immunity. Through the sucking pig compound feed provided by the invention, the problem of weaning stress of the sucking pig is solved; and compared with the common piglet feed, the morbidity is greatly reduced, the feed intake and daily gain are increased, and the material-meat ratio, morbidity and mortality are reduced.

The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.

The invention discloses a pig feed and application thereof, belonging to the technical field of sow feeding. Physiological stages of a pregnant sow are further subdivided and detailed according to physiological characteristics and nutritional requirements of the sow during a pregnancy period, the feed suitable for each stage is provided according to the nutritional requirements of the pregnant sow at each stage each day, and a reasonable and detailed feeding method is designed by combination with body conditions, feeding environments and the like of different pregnant sows, so that the exercise of the pregnant sow can be effectively increased, nutritional substances can be accurately and timely fed, the functions of a digestive absorption system and an immunity system of the pregnant sow can be promoted and improved, the number of living piglets is remarkably increased, the embryo mortality is reduced, the birth weight of the piglets is increased, and the uniformity of the piglets is improved.

A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.

A method of improving longevity and/or alleviating a symptom of aging or preventing age related diseases is provided. The method includes a step in which the subject's average and type of daily protein intake, IGF-I, and IGFBP1 levels, and risk factors for overall mortality, cancer and diabetes are determined. With respect to protein consumption, the relative amounts of protein calories from animal and plant sources are determined. A periodic normal calorie or low calorie but low protein fasting mimicking diet with frequencies of every 2 weeks to 2 months is provided to the subject if the subject's average daily protein intake level and type and/or IGF-I levels, and/or IGFBP1 levels is identified as being greater or lower than a predetermined cutoff intake/level and if the subject is younger than a predetermined age. The method is also shown to alleviate symptoms of chemotoxicity.

The invention discloses a method for propagating market hogs. According to the different growth and physiological stages of the market hogs, the growth of the market hog comprises the stages of lactation and luring, weaning and stress, pigling breeding, growing development and beef gain, fodder with good nutrition, smell, and luring performance is provided in the stage of lactation and luring; fodder with diarrhea resistance and high nutrition concentration and capable of keeping the healthy of intestinal tract is provided in the stage of weaning and stress; fodder capable of strengthening immunity, promoting growth and exercising the intestinal tract is provided in the pigling breeding; fodder for increasing nutrition and protein synthesis is provided in the stage of growing development;the fodder with high energy and high amino acid is provided in the beef gain. According to the method, the fodder is schemed according to the physiology and development stage and the stress conditions; the method has the advantages of low mortality, quick growth speed, short propagation period, low feed conversion ratio, high weight and the like; in addition, the propagation cost of the market hog is lowered, and the economic benefits of propagating market hog are improved.

An manned, mobile traffic enforcement platform with aimable violation and documentation devices employing digital video and still images, incorporating contextual information as well as data input by the system operator and driver. The mobile enforcement platform (MEP) is operated by a trained and authorized system operator (typically a police officer trained and experienced in traffic enforcement) who applies pre-determined criteria, protocols, procedures and routines that are approved and authorized by the user-jurisdiction for use with the MEP system. MEP's aimable devices support detection, identification, and documentation of violations occurring in any of several lanes behind or in front of the moving MEP vehicle. MEP also can be used from the roadside. The violation information and documentation can be transmitted to a fixed facility for citation processing or it can be transferred in batches over landlines or by direct link for later citation processing. MEP is designed to capture all types of moving violations, including aggressive driving and reckless driving, in readily retrievable documentation that will support citation preparation and can even be provided with the citation to substantiate the content as required by the respective jurisdiction. The MEP operator or driver also can identify gross violations to police dispatchers for attempted interception of the violator by other police units. MEP also generates traffic-related information of interest to planners and police enforcement and can perform homeland security monitoring tasks as well as other surveillance activities. MEP is a traffic enforcement tool that is designed to greatly expand police productivity, reduce police officer paperwork and court time, increase enforcement credibility (eventually reducing court caseloads), reduce crash costs and fatalities, and dramatically improve highway safety.

The present disclosure identifies a novel subtype of follicular lymphoma (FL) characterized by dysregulation of the cyclin/CDK/RB proliferative pathway. This subtype of FL is associated with increased malignancy and mortality, relative to FL which is not associated with cell cycle dysregulation. Accordingly, this disclosure presents novel methods to subtype FL and stratify patient risk by detection of biomarkers associated with RB inactivation. This disclosure further presents novel therapies for the treatment of FL subtyped by inactivation of RB.

The present invention provides a new class of peptides related to rapid replication and high human mortality, and their use in diagnosing, preventing and treating disease including vaccines and therapeutics for emerging viral diseases and methods of identifying the new class of peptides and related structures.